Biotech and Pharmaceuticals Biotechnology

More

  • What's coming in biotech?

    "The market is very favorable for biotech these days," says Les Funtleyder, Bluecloud Healthcare, in discussing growth in the space.

  • Biogen CEO: Want to stop inversions? Reform tax code

    CNBC's Meg Tirrell speaks to Dr. George Scangos, Biogen Idec CEO, about the company's Q2 earnings surge, drug pipeline, and America's tax code. Scangos says we need a corporate tax rate that is competitive with rest of the world and a territorial tax system.

  • Faber Report: Puma Biotech surges

    CNBC's David Faber reports Puma Biotechnology surges on positive results for a breast cancer drug.

  • Analyst calls out Yellen's biotech comments

    Mark Schoenbaum, ISI Group, explains why his views differ from Janet Yellen on whether the biotech sector is forming a bubble.

  • How will Yellen's comments impact US stocks?

    Dodge Dorland, Chairman & Chief Investment Officer at Landor & Fuest Capital Managers, says social media and biotech stocks may see more downside in the short run.

  • Fed hits social, tech stocks

    After Janet Yellen's comments on stretched valuations in the social media and biotech sectors, CNBC's Seema Mody looks at what stocks are taking the biggest hit.

  • Next global epidemic?

    CNBC's Meg Tirrell reports which biotech companies are working on what analysts say could be the next big biotech catalyst known as NASH, or nonalcoholic steatohepatitis.

  • Acorda 'firmly on the side of research': CEO

    Ron Cohen, Acorda Therapeutics CEO, discusses merger activity in the pharma sector and whether his company is planning an acquisition.

  • Biotech buys right now

    The S&P Biotech ETF is down 7 percent this week. Robyn Karnauskas, Deutsche Bank biotechnology director, shares her large and small cap picks.

  • Rough day for biotech

    CNBC's Meg Tirrell reports biotech stocks are performing lower than the broader markets.

  • Protect yourself from fake medicine

    CNBC's Scott Cohn follows up on his investigation into the high cost of prescription drugs and reports how consumers can protect themselves from getting fake medicine.

  • Incubating biotech's boom

    Quincy College in Massachusetts created a two year program to fill bio-manufacturing technician positions. CNBC's Mary Thompson reports how the school is fueling job growth.

  • Prescription drugs: Risk vs. cost

    Due to the high cost of prescription drugs, many in the U.S. look overseas to save money. CNBC's Scott Cohn discusses if people are putting themselves at risk or beating big drug companies at their own game.

  • Best time to buy Celgene, Vertex & more

    The biotech ETF soared 67 percent in 2013, but has since been bumpy. Discussing winning and losing stocks in the industry, with Mark Schoenebaum, ISI pharma/biotech analyst.

  • Bone disease breakthrough

    Emil Kakkis, Ultragenyx founder & CEO, discusses the beginning of its drug KRN23's phase 2 pediatric study to treat 30 kids with bone disorder X-linked hypophosphatemia (XLH).

  • Vertex CEO on big cystic fibrosis breakthrough

    CNBC's Meg Tirrell speaks to Vertex Pharmaceuticals CEO Dr. Jeffrey Leiden, about its promising two-drug cystic fibrosis treatment, and what it means for sufferers of the disease. Leiden also explains what goes into the pricing of an "orphan drug."

  • Vertex soars on cystic fibrosis innovation

    CNBC's Meg Tirrell reports Vertex Pharmaceuticals' cystic fibrosis combination of Kalydeco and Lumacaftor has expanded their patient population.

  • Vertex's cystic fibrosis breakthrough

    CNBC's Meg Tirell reports Vertex Pharmaceuticals' treatment for cystic fibrosis has succeeded in late stage trials. Vertex will now file applications for U.S. and Europe approval in Q4.

  • Cubist advances Sivextro

    Michael Bonney, Cubist Pharmaceuticals CEO, discusses the FDA's approval of Sivextro, a new antibiotic designed to treat skin infections. Bonney also explains why so many pharma companies have left the antibiotic space.

  • Big event coming in biotech

    CNBC's Meg Tirrell reports on everything investors need to know about Vertex Pharmaceuticals' upcoming data release on a combination of drugs for cystic fibrosis.